After all, the human genome consists of three billion nucleotide bases that encode about 100,000 genes. Of these genes, perhaps 3,000 to 10,000 may have uses for curing diseases. Of course, there are a variety of software firms that want to make genomics development much easier. The company has a product called Deltabase. This is a comprehensive database of about 1,000 genes.
Companies have access to the information through a subscription model.
With this information, companies can validate new drugs and get them to market faster and more cost-effectively. With this, genes can be better identified, as well as inactivated. The company is very early stage, as reflected in its recent financials. Although, subscription revenues could prove to be very lucrative. Of course, Deltagen is showing significant losses.